Anti-leukemia activity of in vitro-expanded human gamma delta T cells in a xenogeneic Ph+ leukemia model

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Siegers, Gabrielle M ^a   Felizardo, Tania C ^a   Mark Mathieson, A ^a   Kosaka, Yoko ^a   Wang, Xing Hua ^a   Medin, Jeffrey A ^a   Keating, Armand ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; CD16 ANTIGEN; CD45RO ANTIGEN; CD56 ANTIGEN; FAS ANTIGEN; NATURAL KILLER CELL RECEPTOR NKG2D; LYMPHOCYTE ANTIGEN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ARTICLE; BIOLUMINESCENCE; BONE MARROW; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; EFFECTOR CELL; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN CELL; LEUKEMIA; MEMORY CELL; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; T CELL DEPLETION; XENOGRAFT; ADOPTIVE IMMUNOTHERAPY; ANIMAL; CELL CULTURE; CELL PROLIFERATION; CELL STRAIN K 562; CYTOTOXIC T LYMPHOCYTE; DISEASE MODEL; EVALUATION; GENETICS; IMMUNOLOGY; MALE; METABOLISM; METHODOLOGY; NONOBESE DIABETIC MOUSE; PATHOLOGY; PHILADELPHIA 1 CHROMOSOME; PHYSIOLOGY; TRANSGENIC MOUSE; TRANSPLANTATION;

MUS;

ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY, ADOPTIVE; K562 CELLS; LEUKEMIA; MALE; MICE; MICE, INBRED NOD; MICE, TRANSGENIC; PHILADELPHIA CHROMOSOME; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION, HETEROLOGOUS;

EID: 79751483980     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016700     Document Type: Article

References (47)

1. Lamb LS, Jr., Lopez RD (2005) Gammadelta T cells: a new frontier for immunotherapy? Biol Blood Marrow Transplant 11: 161-168.
2. Ensslin AS, Formby B (1991) Comparison of cytolytic and proliferative activities of human gamma delta and alpha beta T cells from peripheral blood against various human tumor cell lines. J Natl Cancer Inst 83: 1564-1569.
3. Zheng BJ, Chan KW, Im S, Chua D, Sham JS, et al. (2001) Anti-tumor effects of human peripheral gammadelta T cells in a mouse tumor model. Int J Cancer 92: 421-425.
4. Kabelitz D, Wesch D, He W (2007) Perspectives of gammadelta T cells in tumor immunology. Cancer Res 67: 5-8.
5. Viey E, Lucas C, Romagne F, Escudier B, Chouaib S, et al. (2008) Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cell carcinoma patients. J Immunother 31: 313-323.
6. Wright A, Lee JE, Link MP, Smith SD, Carroll W, et al. (1989) Cytotoxic T lymphocytes specific for self tumor immunoglobulin express T cell receptor delta chain. J Exp Med 169: 1557-1564.
7. Freedman MS, D'Souza S, Antel JP (1997) gamma delta T-cell-human glial cell interactions. I. In vitro induction of gammadelta T-cell expansion by human glial cells. J Neuroimmunol 74: 135-142.
8. Vollenweider I, Vrbka E, Fierz W, Groscurth P (1993) Heterogeneous binding and killing behaviour of human gamma/delta-TCR+ lymphokine-activated killer cells against K562 and Daudi cells. Cancer Immunol Immunother 36: 331-336.
9. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, et al. (2000) Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96: 384-392.
10. Aswald JM, Wang XH, Aswald S, Lutynski A, Minden MD, et al. (2006) Flow cytometric assessment of autologous gammadelta T cells in patients with acute myeloid leukemia: potential effector cells for immunotherapy? Cytometry B Clin Cytom 70: 379-390.
11. Lamb LS, Jr., Henslee-Downey PJ, Parrish RS, Godder K, Thompson J, et al. (1996) Increased frequency of TCR gamma delta + T cells in disease-free survivors following T cell-depleted, partially mismatched, related donor bone marrow transplantation for leukemia. J Hematother 5: 503-509.
12. Lamb LS, Jr., Musk P, Ye Z, van Rhee F, Geier SS, et al. (2001) Human gammadelta(+) T lymphocytes have in vitro graft vs leukemia activity in the absence of an allogeneic response. Bone Marrow Transplant 27: 601-606.
13. Kobayashi H, Tanaka Y, Yagi J, Osaka Y, Nakazawa H, et al. (2007) Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother 56: 469-476.
14. Kobayashi H, Tanaka Y, Shimmura H, Minato N, Tanabe K (2010) Complete remission of lung metastasis following adoptive immunotherapy using activated autologous gammadelta T-cells in a patient with renal cell carcinoma. Anticancer Res 30: 575-579.
15. Nakajima J, Murakawa T, Fukami T, Goto S, Kaneko T, et al. (2010) A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gammadelta T cells. Eur J Cardiothorac Surg 37: 1191-1197.
16. Rowley JD (1973) Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243: 290-293.
17. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, et al. (1984) Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36: 93-99.
18. de Klein A, van Kessel AG, Grosveld G, Bartram CR, Hagemeijer A, et al. (1982) A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 300: 765-767.
19. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, et al. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2: 561-566.
20. Deininger MW (2008) Milestones and monitoring in patients with CML treated with imatinib. Hematology Am Soc Hematol Educ Program. pp 419-426.
21. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, et al. (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355: 2408-2417.
22. Bixby D, Talpaz M (2009) Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology Am Soc Hematol Educ Program. pp 461-476.
23. Mustjoki S, Rohon P, Rapakko K, Jalkanen S, Koskenvesa P, et al. (2010) Low or undetectable numbers of Philadelphia chromosome-positive leukemic stem cells (Ph(+)CD34(+)CD38(neg)) in chronic myeloid leukemia patients in complete cytogenetic remission after tyrosine kinase inhibitor therapy. Leukemia 24: 219-222.
24. Bocchia M, Gentili S, Abruzzese E, Fanelli A, Iuliano F, et al. (2005) Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 365: 657-662.
25. Kreutzman A, Juvonen V, Kairisto V, Ekblom M, Stenke L, et al. (2010) Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 116: 772-782.
26. Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, et al. (2009) Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 23: 1398-1405.
27. Keating A MP, Bernstein ID, Papayannopoulou T, Raskind W, Singer JW () EM-2 and EM-3: two new Ph'+ myeloid cell lines. In: GDM PA, ed. Symposia on Molecular and Cellular Biology, New Series; 1983; UCLA. New York: Alan R. Liss. pp 513-520.
28. Amendola M, Venneri MA, Biffi A, Vigna E, Naldini L (2005) Coordinate dualgene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters. Nat Biotechnol 23: 108-116.
29. Yoshimitsu M, Sato T, Tao K, Walia JS, Rasaiah VI, et al. (2004) Bioluminescent imaging of a marking transgene and correction of Fabry mice by neonatal injection of recombinant lentiviral vectors. Proc Natl Acad Sci U S A 101: 16909-16914.
30. Suck G, Branch DR, Smyth MJ, Miller RG, Vergidis J, et al. (2005) KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity. Exp Hematol 33: 1160-1171.
31. McCoy JL, Herberman RB, Rosenberg EB, Donnelly FC, Levine PH, et al. (1973) 51 Chromium-release assay for cell-mediated cytotoxicity of human leukemia and lymphoid tissue-culture cells. Natl Cancer Inst Monogr 37: 59-67.
32. Dieli F, Poccia F, Lipp M, Sireci G, Caccamo N, et al. (2003) Differentiation of effector/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites. J Exp Med 198: 391-397.
33. Espinosa E, Belmant C, Pont F, Luciani B, Poupot R, et al. (2001) Chemical synthesis and biological activity of bromohydrin pyrophosphate, a potent stimulator of human gamma delta T cells. J Biol Chem 276: 18337-18344.
34. Roelofs AJ, Jauhiainen M, Monkkonen H, Rogers MJ, Monkkonen J, et al. (2009) Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol 144: 245-250.
35. Salot S, Bercegeay S, Dreno B, Saiagh S, Scaglione V, et al. (2009) Large scale expansion of Vgamma9Vdelta2 T lymphocytes from human peripheral blood mononuclear cells after a positive selection using MACS ''TCR gamma/delta+ T cell isolation kit''. J Immunol Methods 347: 12-18.
36. Dokouhaki P, Han M, Joe B, Li M, Johnston MR, et al. (2010) Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta T cells: A new approach. Cancer Lett 297: 126-136.
37. Braakman E, Sturm E, Vijverberg K, van Krimpen BA, Gratama JW, et al. (1991) Expression of CD45 isoforms by fresh and activated human gamma delta T lymphocytes and natural killer cells. Int Immunol 3: 691-697.
38. Rohon P, Porkka K, Mustjoki S (2010) Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. Eur J Haematol 85: 387-398.
39. Poccia F, Boullier S, Lecoeur H, Cochet M, Poquet Y, et al. (1996) Peripheral V gamma 9/V delta 2 T cell deletion and anergy to nonpeptidic mycobacterial antigens in asymptomatic HIV-1-infected persons. J Immunol 157: 449-461.
40. Alexander AA, Maniar A, Cummings JS, Hebbeler AM, Schulze DH, et al. (2008) Isopentenyl pyrophosphate-activated CD56+ {gamma}{delta} T lymphocytes display potent antitumor activity toward human squamous cell carcinoma. Clin Cancer Res 14: 4232-4240.
41. Angelini DF, Borsellino G, Poupot M, Diamantini A, Poupot R, et al. (2004) FcgammaRIII discriminates between 2 subsets of Vgamma9Vdelta2 effector cells with different responses and activation pathways. Blood 104: 1801-1807.
42. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, et al. (1999) Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285: 727-729.
43. Hayday AC (2000) [gamma][delta] cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol 18: 975-1026.
44. Bonneville M, Scotet E (2006) Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors. Curr Opin Immunol 18: 539-546.
45. Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, et al. (2005) Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 174: 6477-6489.
46. D'Asaro M, La Mendola C, Di Liberto D, Orlando V, Todaro M, et al. (2010) V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronatesensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells. J Immunol 184: 3260-3268.
47. Kabelitz D, Wesch D, Pitters E, Zoller M (2004) Characterization of tumor reactivity of human V gamma 9V delta 2 gamma delta T cells in vitro and in SCID mice in vivo. J Immunol 173: 6767-6776.